MRA’s 2024-2025 Annual Report showcases the innovation, imagination, and investments that are bringing cutting edge science from bench to bedside. Perhaps more importantly, this report highlights how the power of collaboration can’t be overstated when it comes to MRA’s research priority areas: treatment resistant cutaneous melanoma, rare melanomas, brain and central nervous system metastases, and prevention, risk prediction, and diagnosis.
